Poolbeg Pharma Plc has appointed Adrian Kilcoyne to its scientific advisory board. Dr Kilcoyne brings over 20 years’ drug development expertise in oncology and immunology and, in particular, specialist knowledge of haematological malignancies, T cell therapies and cytokine release syndrome. He is currently chief medical officer at Cellectis focusing on the development of allogeneic CAR-T therapies. He has an MD in medicine from Trinity College, Dublin, Ireland. Poolbeg’s lead asset POLB 001, a kinase inhibitor targeting cancer immunotherapy-induced CRS, is in a clinical trial.
Poolbeg announced the appointment on 12 March 2026.
Copyright 2026 Evernow Publishing Ltd